Currently, an in vivo study focusing on the neuroprotective effect of oral administration of Zorifertinib (an epidermal growth factor receptor-tyrosine kinase inhibitor) is ongoing to demonstrate the application of cancer target therapy for acute brain damages. This evidence concerns the gene EGFR and cancer.